Antimicrobial resistance is outpacing the diagnostic tools meant to contain it, and a new review argues that artificial intelligence fused with biomedical microdevices could close that gap. Writing in Biomedical Microdevices, researchers Nirmal Kumar Manisekaran, Pallavi Tiwari and Pasupathi Rathinasabapathi examine how AI can be layered onto microfluidic lab-on-chip platforms, electrochemical and optical biosensors, and CRISPR-based technologies to detect resistance faster than conventional culture-based testing. The review, published on 3 November 2026 as volume 28, article number 75, positions AI not as a replacement for biosensors but as the intelligence layer that makes their complex outputs clinically actionable.
The core problem the authors identify is turnaround time. Culture-based antimicrobial susceptibility testing, the clinical gold standard, takes extended periods to deliver results, delaying timely antimicrobial selection and stewardship decisions. Molecular diagnostics can rapidly identify resistance determinants, but the review stresses a critical caveat: identifying a resistance gene does not guarantee that the organism will express phenotypic resistance. AI-enhanced biosensing is presented as a route to combine speed with better predictive interpretation of what the resistance actually means for treatment.
The review details where machine learning earns its place in the biosensor pipeline. AI is applied for signal processing, noise reduction, and pattern recognition, tasks that are especially demanding when biosensors generate complex, multiplexed outputs from real biological samples. Rather than requiring a specialist to interpret raw electrochemical or optical traces, embedded AI models can classify patterns, resolve overlapping signals from multiple targets, and translate sensor data into predictive interpretations that clinicians can act on. This multiplexed detection capability is central to the vision of a single chip identifying multiple resistance mechanisms simultaneously.
The authors are notably blunt about why so many promising prototypes fail in the field. They catalogue translational challenges including biofouling, matrix interference, sample-preparation variability, bubble formation, evaporation, signal drift, and invalid-test rates. Device reproducibility and inadequate standardisation of reporting and validation are flagged as systemic weaknesses across the field. These are not minor engineering footnotes; a biosensor that works with purified controls but degrades in blood, urine, or wastewater cannot serve clinical or surveillance purposes, and the review treats these failure modes as first-order design constraints rather than afterthoughts.
For AI to run on portable point-of-care devices rather than cloud servers, the review considers the embedded requirements: memory, computational resources, latency, and energy efficiency. A diagnostic deployed in a resource-limited clinic or a remote veterinary setting cannot depend on high-bandwidth connectivity or power-hungry processors. The authors frame these hardware constraints as integral to the design of any AI model intended for decentralised deployment, effectively arguing that model architecture and device engineering must be co-designed from the outset.
The review also draws a distinction that is often blurred in the diagnostics literature: analytical, clinical, and operational validation are separate hurdles. A sensor may detect a target analytically in buffer, yet fail to deliver clinically meaningful results in patient specimens, or pass clinical evaluation but collapse operationally when used by minimally trained staff in real-world conditions. The authors emphasise prospective multicentre evaluation using representative specimens and reference AST methods as the benchmark that AI-enabled devices must meet before translation, rather than retrospective single-lab demonstrations.
Beyond the clinic, the review extends the vision to decentralised AMR surveillance across wastewater, agricultural, veterinary, and environmental settings within a One Health framework. Resistance genes do not respect the boundary between hospital and farm, and the same AI-enhanced microdevices designed for rapid clinical detection could, in principle, monitor resistance emergence in environmental reservoirs. This surveillance ambition is what elevates the review beyond a summary of sensor technologies: it frames AI-enabled microdevices as infrastructure for tracking resistance at population and ecosystem scale.
The path to that scale is conditional. The authors state that translation will require standardised datasets, generalisable and explainable AI, scalable manufacturing, regulatory oversight, data governance, and equitable deployment. Each requirement addresses a documented failure point: models trained on narrow datasets that fail on new populations, black-box predictions that clinicians cannot trust, prototypes that cannot be manufactured at volume, and technologies that reach wealthy markets first while the highest-burden regions wait.
The overall verdict is measured rather than triumphant. The review concludes that AI-integrated biomedical microdevices represent a promising approach to rapid, decentralised, and actionable AMR diagnostics and surveillance, contingent on robust real-world validation. For a field where culture-based testing remains clinically important despite its delays, and where molecular assays predict phenotype imperfectly, that contingency is the entire story: the technology is promising precisely to the degree that prospective, multicentre, real-world evidence can be produced to support it.
Subject of Research: Integration of artificial intelligence with biomedical microdevices and biosensors for rapid antimicrobial resistance diagnostics and One Health surveillance
Article Title: AI-enhanced biosensing for antimicrobial resistance: translating rapid diagnostics to global surveillance
Article References: Manisekaran, N. K., Tiwari, P., & Rathinasabapathi, P. (2026). AI-enhanced biosensing for antimicrobial resistance: translating rapid diagnostics to global surveillance. Biomedical Microdevices, 28(4), Article 75. https://doi.org/10.1007/s10544-026-00853-7
Image Credits: AI Generated
DOI: 10.1007/s10544-026-00853-7
Keywords: antimicrobial resistance, biosensors, artificial intelligence, microfluidics, point-of-care diagnostics, lab-on-chip, CRISPR, One Health, surveillance, diagnostic validation, AI-enhanced, biosensing
News Source: Kristina Jarvis. (November 4, 2026). AI-powered biosensors aim to speed antimicrobial resistance detection from clinic to global surveillance. Scienmag.
